🔗 Visit the ClinicalTrials.gov page for NCT00604721
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. | Oncotarget | 2012 | 1.55 |
| 2 | Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. | J Clin Oncol | 2011 | 1.52 |
| 3 | The MAPK pathway across different malignancies: a new perspective. | Cancer | 2014 | 1.22 |
| 4 | Targeted therapies in the treatment of advanced hepatocellular carcinoma. | Clin Med Insights Oncol | 2013 | 0.83 |